UNITY’s second drug candidate, UBX1325, targets specific members of the Bcl-2 family of apoptosis-resistance proteins, which some senescent cells use to evade destruction and remain alive.

UNITY evaluated UBX1325 for the potential treatment of age-related diseases of the eye, including age-related macular degeneration (ARMD), diabetic macular edema (DME), and proliferative diabetic retinopathy.

In July 2021, UNITY issued a press release announcing the 8-week preliminary results of a phase I study of UBX1325 in patients with DME and wet ARMD. Although a safety study, the results showed that — along with being safe — UBX1325 improved vision and structural measures of disease progression (central subfield thickness (CST), and sub- and intra-retinal fluid). In October 2021, the 12-week results showed sustained improvements in vision & structure. Further results released in November 2021 showed that after 24 weeks DME patients had gained almost 10 ETDRS letters in best corrected visual acuity.

UNITY then launched a Phase IIa trial in subjects with DME, and enrolled additional ARMD patients in the Phase I trial to support a Phase II trial for ARMD originally scheduled to start in the first half of 2022.

On March 27, 2023 UNITY announced the results of the ENVISION study, which tested UBX1325 in persons with wet ARMD who were not achieving optimum benefit with ongoing standard-of-care anti-VEGF therapy. UBX1325 maintained visual acuity in patients through 24 weeks, with less than one ETDRS letter lost on average and most patients not requiring a “rescue” round of anti-VEGF treatment. However, UBX1325 monotherapy did not achieve its primary endpoint (noninferiority) through 24 weeks, in part due to an unexpected gain of 3.5 EDTRS letters in the anti-VEGF control arm.

In May of 2025, UNITY announced the complete 36-week results from the Phase IIb ASPIRE trial in DME. UBX1325 was statistically non-inferior to anti-VEGF therapy (aflibercept/Eylea®) at week 36 and at most interim weeks, but did not achieve noninferiority at 20 weeks, which was the prespecified endpoint.

The company announced that it would lay off its entire workforce and was working to minimize cash burn as it pursues new partnerships with companies with deep experience in ophthalmologic diseases.As of September 2025, the company’s website has been reduced to a single page announcing that the company is no longer operating.